TY - JOUR
T1 - A PROTAC degrader suppresses oncogenic functions of PTK6 inducing apoptosis of breast cancer cells
AU - Martinez, Criseyda
AU - Xiong, Yan
AU - Bartkowski, Alison
AU - Harada, Ibuki
AU - Ren, Xiaoxiao
AU - Byerly, Jessica
AU - Port, Elisa
AU - Jin, Jian
AU - Irie, Hanna
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024
Y1 - 2024
N2 - Protein tyrosine kinase 6 (PTK6), a non-receptor tyrosine kinase, is an oncogenic driver in many tumor types. However, agents that therapeutically target PTK6 are lacking. Although several PTK6 kinase inhibitors have been developed, none have been clinically translated, which may be due to kinase-independent functions that compromise their efficacy. PTK6 kinase inhibitor treatment phenocopies some, but not all effects of PTK6 downregulation. PTK6 downregulation inhibits growth of breast cancer cells, but treatment with PTK6 kinase inhibitor does not. To chemically downregulate PTK6, we designed a PROTAC, MS105, which potently and specifically degrades PTK6. Treatment with MS105, but not PTK6 kinase inhibitor, inhibits growth and induces apoptosis of breast cancer cells, phenocopying the effects of PTK6 (short hairpin RNA) shRNA/CRISPR. In contrast, both MS105 and PTK6 kinase inhibitor effectively inhibit breast cancer cell migration, supporting the differing kinase dependencies of PTK6’s oncogenic functions. Our studies support PTK6 degraders as a preferred approach to targeting PTK6 in cancer.
AB - Protein tyrosine kinase 6 (PTK6), a non-receptor tyrosine kinase, is an oncogenic driver in many tumor types. However, agents that therapeutically target PTK6 are lacking. Although several PTK6 kinase inhibitors have been developed, none have been clinically translated, which may be due to kinase-independent functions that compromise their efficacy. PTK6 kinase inhibitor treatment phenocopies some, but not all effects of PTK6 downregulation. PTK6 downregulation inhibits growth of breast cancer cells, but treatment with PTK6 kinase inhibitor does not. To chemically downregulate PTK6, we designed a PROTAC, MS105, which potently and specifically degrades PTK6. Treatment with MS105, but not PTK6 kinase inhibitor, inhibits growth and induces apoptosis of breast cancer cells, phenocopying the effects of PTK6 (short hairpin RNA) shRNA/CRISPR. In contrast, both MS105 and PTK6 kinase inhibitor effectively inhibit breast cancer cell migration, supporting the differing kinase dependencies of PTK6’s oncogenic functions. Our studies support PTK6 degraders as a preferred approach to targeting PTK6 in cancer.
KW - BRK
KW - PROTAC
KW - PTK6
KW - apoptosis
KW - breast cancer
KW - degraders
UR - http://www.scopus.com/inward/record.url?scp=85210747834&partnerID=8YFLogxK
U2 - 10.1016/j.chembiol.2024.10.008
DO - 10.1016/j.chembiol.2024.10.008
M3 - Article
C2 - 39541980
AN - SCOPUS:85210747834
SN - 2451-9448
JO - Cell Chemical Biology
JF - Cell Chemical Biology
ER -